MedPath

LG Chem, Ltd.

🇰🇷South Korea
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

11

NMPA:11

Drug Approvals

Gemifloxacin Mesylate Tablets

Product Name
吉速星
Approval Number
国药准字HJ20170329
Approval Date
Oct 10, 2023
NMPA

Gemifloxacin Mesylate Tablets

Product Name
吉速星
Approval Number
国药准字HJ20170326
Approval Date
Oct 10, 2023
NMPA

BDDE-Crosslinked Sodium Hyaluronate Injection

Product Name
丁甘交联玻璃酸钠注射液
Approval Number
国药准字HJ20233147
Approval Date
Mar 28, 2023
NMPA

Recombinant Human Growth Hormone for Injection

Product Name
尤得盼
Approval Number
国药准字SJ20181002
Approval Date
Nov 17, 2022
NMPA

Recombinant Human Growth Hormone for Injection

Product Name
尤得盼
Approval Number
国药准字SJ20181003
Approval Date
Nov 17, 2022
NMPA

Recombinant Human Follitropin Prefilled Syringe

Product Name
芳乐舒
Approval Number
国药准字SJ20210005
Approval Date
Apr 7, 2021
NMPA

Recombinant Human Follitropin Prefilled Syringe

Product Name
芳乐舒
Approval Number
国药准字SJ20210008
Approval Date
Apr 7, 2021
NMPA

Recombinant Human Follitropin Prefilled Syringe

Product Name
芳乐舒
Approval Number
国药准字SJ20210006
Approval Date
Apr 7, 2021
NMPA

Recombinant Human Follitropin Prefilled Syringe

Product Name
芳乐舒
Approval Number
国药准字SJ20210007
Approval Date
Apr 7, 2021
NMPA

Gemifloxacin Mesylate Tablets

Product Name
吉速星
Approval Number
H20170329
Approval Date
Nov 8, 2018
NMPA
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.